This case identifies the different struggles carried out by Pharmaceutical multinational corporation (MNC’S) face while comprehending and analyzing the difficulties of patent law in India what can learn from important pharmaceutical intellectual property (IP) cases being fought in nation’s court. Like most rising markets, India is a new market opportunity for MNC’s and a complicated and challenging environment in which to manage.
Patents and Competitive Dynamics in the Indian Pharma Industry Case Study Solution
For instance, while the patent protection afforded to procedures and products is rigorous, mostly on paper, its enforcement has often been troublesome for MNC’s has has caused hindrance for MNC’s to earn a profitable income. The case study illustrates some of current judgments handed down by Indian courts relating to high profile pharmaceutical IP cases (including Novartis' Glivec and Bayer's Nexavar) with a view to helping pupils formulate strategies to overcome value appropriation issues in India.
PUBLICATION DATE: March 09, 2015 PRODUCT #: ISB051-PDF-ENG
This is just an excerpt. This case is about STRATEGY about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
How the US lost out on IPhone work
Castlight Health: Disrupting the Health Care Industry
The Paris Opera Hotel
Recruiting for a Multinational Enterprise in China
Stalemate at the WTO: TRIPS, Agricultural Subsidies, and the Doha Round
The Full Yield
Beyond Strategic Thinking: Strategy as Experienced
GLOBIS
Incentive Strategy II: Executive Compensation and Ownership Structure
EAC Nutrition: Regional Expansion Strategy
